Company profile for EpimAb Biotherapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary, unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and...
EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company based in Shanghai with a proprietary, unique and efficient technology called FIT-Ig® (Fabs-In-Tandem Immunoglobulin) that generates bispecific molecules with antibody-like properties. With this innovative platform, EpimAb is creating a potentially game-changing pipeline of its own novel bispecific antibody therapeutics focused around immuno-oncology and other areas of high value to patients. EpimAb is further committed to diversifying its portfolio of FIT-Igs together with partners in order to further validate the flexibility and robustness of the format.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
China
Address
Address
6th Floor, Building 2, Jinchuang Building, 702 Zhongke Road Zhangjiang High-T...
Telephone
Telephone
+86-21-61951000
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/05/27/3088426/0/en/Juri-Biosciences-a-TCG-Labs-Soleil-Portfolio-Company-and-EpimAb-Biotherapeutics-Enter-into-a-Worldwide-Licensing-Agreement-for-KLK2-Directed-T-Cell-Engager-in-Metastatic-Prostate-C.html

GLOBENEWSWIRE
27 May 2025

https://www.globenewswire.com/news-release/2025/02/27/3033551/0/en/Medigene-and-EpimAb-Biotherapeutics-Enter-into-a-Co-Development-Partnership-for-TCR-Guided-T-Cell-Engagers.html

GLOBENEWSWIRE
27 Feb 2025

https://www.businesswire.com/news/home/20241216821817/en

BUSINESSWIRE
16 Dec 2024

https://www.businesswire.com/news/home/20240305434743/en/EpimAb-Biotherapeutics-to-Present-Late-breaking-Abstract-on-Preclinical-Results-of-EMB-07-at-the-2024-American-Association-for-Cancer-Research-Annual-Meeting

BUSINESSWIRE
05 Mar 2024

https://www.businesswire.com/news/home/20231031183230/en

BUSINESSWIRE
31 Oct 2023

https://www.businesswire.com/news/home/20231011383566/en

BUSINESSWIRE
12 Oct 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty